Abstract: Method for enantioseparation of a chiral system with compound formation comprising a pair of enantiomers. The method comprises the steps of: placing the chiral system to be processed, which is optically enriched by a target enantiomer, in the 3-phase region of the ternary phase diagram of chiral compound forming systems to achieve the establishment of the solid/liquid phase equilibria; phase-separating the liquid and solid phase formed by the placing step; shifting the eutectic composition of the remaining liquid towards a lower eutectic composition (xE) until the overall composition is located in the 2-phase region of the ternary phase diagram of chiral compound forming systems; and performing crystallization in the 2-phase region of the ternary phase diagram for obtaining the target enantiomer in the solid phase. In some cases the shifting step can be skipped.

Abstract: Described is a method for analyzing the metabolites of a biological sample which comprises quantitatively determining one or more metabolites in said sample in a way that said quantitative determination resolves isotopic mass differences within one metabolite, said method being characterized in that the sample comprises or is derived from a cell which has been maintained under conditions allowing the uptake of an isotopically labeled metabolizable compound so that the metabolites in said cell are saturated with the isotope with which said metabolizable compound is labeled. This method may further comprise, prior to quantitative determining the metabolites, combining the biological sample (i.e. the first biological sample) with a second biological sample in which the metabolites are not isotopically labeled or are isotopically labeled differently from the first biological sample; and determining in said biological samples the relative quantity of metabolites which differ by their isotopical label.

Abstract: The present invention relates to a method of preventing or treating a disease correlated with or caused by non-physiologically increased intracellular levels of the catalytic subunit of microtubule-associated protein phosphatase 2A (PP2Ac) comprising administering to a subject affected by said disease or in danger of developing said disease a pharmaceutically effective amount of a protein selected from the group of MID1 or MID2 or a nucleic acid encoding said protein.

Abstract: Described is a method for analysing the metabolites of a biological sample which comprises quantitatively determining one or more metabolites in said sample in a way that said quantitative determination resolves isotopic mass differences within one metabolite, said method being characterized in that the sample comprises or is derived from a cell which has been maintained under conditions allowing the uptake of an isotopically labeled metabolizable compound so that the metabolites in said cell are saturated with the isotope with which said metabolizable compound is labeled. This method may further comprise, prior to quantitative determining the metabolites, combining the biological sample (i.e. the first biological sample) with a second biological sample in which the metabolites are not isotopically labeled or are isotopically labeled differently from the first biological sample; and determining in said biological samples the relative quantity of metabolites which differ by their isotopical label.

Abstract: A method is described for inhibiting urokinase plasminogen activator in a human or animal patient.

Abstract: The present invention relates to novel cytoplasmic tyrosine kinases isolated from megakaryoctyes (megakaryocyte kinases or MKKs) which are involved in cellular signal transduction pathways and to the use of these novel proteins in the diagnosis and treatment of disease. The present invention further relates to specific megakaryocyte kinases, designated MKK1, MKK2, and MKK3, and their use as diagnostic and therapeutic agents.

Abstract: The present invention provides a vaccine against Lyme disease, wherein it contains one or more monoclonal antibodies which are specific for the 31 kD antigen (OspA) or the 34 kD antigen (OspB) of Borrelia burgdorferi. The present invention also provides a process for obtaining this vaccine, as well as new monoclonal antibodies and antigens.

Abstract: A novel protein tyrosine phosphatase designated PTP-S31 and its subfamily are identified, as are nucleic acid molecule coding therefor. Included in this family are PTP-S31 proteins or glycoproteins having one, two, or three identified amino acid changes in previously defined consensus sequences in the catalytic phosphatase domains of known protein tyrosine phosphatases. The PTP-S31 proteins or glycoproteins may be produced by recombinant means. Antibodies to PTP-S31 proteins or glycoproteins and nucleic acid constructs coding therefor, and methods for screening molecules which can bind to PTP-S31 proteins or glycoproteins and inhibit or stimulate their enzymatic activity, are provided.

Abstract: The present invention relates to novel cytoplasmic tyrosine kinases isolated from megakaryocytes (megakaryocyte kinases or MKKs) which are involved in cellular signal transduction pathways and to the use of these novel proteins in the diagnosis and treatment of disease. The present invention further relates to specific megakaryocyte kinases, designated MKK1, MKK2 and MKK3, and their use as diagnostic and therapeutic agents.

Abstract: The present invention relates to novel cytoplasmic tyrosine kinases isolated from megakaryocytes (megakaryocyte kinases or MKKs) which are involved in cellular signal transduction pathways and to the use of these novel proteins in the diagnosis and treatment of disease. The present invention further relates to specific megakaryocyte kinases, designated MKK1, MKK2 and MKK3, and their use as diagnostic and therapeutic agents.

Abstract: The invention concerns a new pharmaceutical agent for oral or topical administration in the treatment of protozoal diseases, in particular of leishmaniasis, which contains as the active substance one or several compounds having the general formula I 1

Abstract: The present invention relates to cell lines useful for the screening and identification of compounds that by modulating phosphotyrosine phosphatase activity, modulate insulin receptor type tyrosine kinase mediated signal transduction. Genetically engineered cells expressing IR in culture overcome the effect of insulin on morphology and adhesion when they are also coexpressing RPTP.alpha. or RPTP.epsilon.. Such engineered cell lines may be used to screen and identify non-toxic compounds that could elicit or modulate insulin signal transduction even in the absence of insulin.